179 related articles for article (PubMed ID: 8622042)
41. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
42. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
[TBL] [Abstract][Full Text] [Related]
43. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma.
Walsh C; Wernz JC; Levine A; Rarick M; Willson E; Melendez D; Bonnem E; Thompson J; Shelton B
J Acquir Immune Defic Syndr (1988); 1993 Mar; 6(3):265-71. PubMed ID: 7680712
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Maruyama D
Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
[No Abstract] [Full Text] [Related]
45. Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols.
Tauro S; Cochrane L; Lauritzsen GF; Baker L; Delabie J; Roberts C; Mahendra P; Holte H
Am J Hematol; 2010 Apr; 85(4):261-3. PubMed ID: 20201088
[TBL] [Abstract][Full Text] [Related]
46. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Reiter A; Schrappe M; Parwaresch R; Henze G; Müller-Weihrich S; Sauter S; Sykora KW; Ludwig WD; Gadner H; Riehm H
J Clin Oncol; 1995 Feb; 13(2):359-72. PubMed ID: 7844597
[TBL] [Abstract][Full Text] [Related]
47. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
48. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
49. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
50. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
51. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
[TBL] [Abstract][Full Text] [Related]
52. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
[TBL] [Abstract][Full Text] [Related]
53. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
[TBL] [Abstract][Full Text] [Related]
54. Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen.
Gad-el-Mawla N; Hussein MH; Abdel-Hadi S; el-Taneer O; Adde M; Magrath I
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S20-3. PubMed ID: 2758567
[TBL] [Abstract][Full Text] [Related]
55. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
56. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
58. High-dose methylprednisolone, vincristine, MTX, and ara-C (SOMA) as initial bulk reducing therapy in non-Hodgkin's lymphoma of unfavorable histology: preliminary results of an ongoing phase II study.
van Imhoff GW; Nieweg HO; Halie MR
Semin Oncol; 1987 Jun; 14(2 Suppl 1):98-103. PubMed ID: 3589700
[No Abstract] [Full Text] [Related]
59. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases.
Couderc LJ; Stelianides S; Frachon I; Stern M; Epardeau B; Baumelou E; Caubarrere I; Hermine O
Respir Med; 1999 Jan; 93(1):65-8. PubMed ID: 10464852
[No Abstract] [Full Text] [Related]
60. Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma.
Hasegawa Y; Ninomiya H; Kamoshita M; Ohtani K; Kobayashi T; Kojima H; Nagasawa T; Abe T
Intern Med; 1997 May; 36(5):360-4. PubMed ID: 9213175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]